



OPEN ACCESS

EDITED BY

Alok Raghav,
Ganesh Shankar Vidyarthi Memorial
Medical College, India

REVIEWED BY

Erik Knight,
University of Colorado Boulder,
United States
Jamal Ahmad,
Aligarh Muslim University, India

*CORRESPONDENCE

Dongxia Hu
hudongxia5489@sina.com
Rong Wan
rong87223@163.com

[†]These authors have contributed
equally to this work

SPECIALTY SECTION

This article was submitted to
Clinical Diabetes,
a section of the journal
Frontiers in Endocrinology

RECEIVED 15 April 2022

ACCEPTED 05 August 2022

PUBLISHED 23 August 2022

CITATION

Huang Y, Chen H, Hu D and Wan R
(2022) Blood hemoglobin A1c might
predict adverse differences in heart
rate variability in a diabetic population:
Evidence from the midlife in the
United States (MIDUS) study.
Front. Endocrinol. 13:921287.
doi: 10.3389/fendo.2022.921287

COPYRIGHT

© 2022 Huang, Chen, Hu and Wan. This
is an open-access article distributed
under the terms of the [Creative
Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction
in other forums is permitted, provided
the original author(s) and the
copyright owner(s) are credited and
that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Blood hemoglobin A1c might predict adverse differences in heart rate variability in a diabetic population: Evidence from the Midlife in the United States (MIDUS) study

Ying Huang^{1†}, Hong Chen^{2†}, Dongxia Hu^{1*} and Rong Wan^{3*}

¹Rehabilitation Department, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ²Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ³Jiangxi Key Laboratory of Molecular Medicine, Nanchang, China

Background: Cardiac autonomic neuropathy in population with diabetes mellitus (DM) is frequent and linked with high risk of cardiovascular mortality. However, studies on whether blood hemoglobin A1c (HbA1c) levels are related to adverse differences in heart rate variability (HRV) in individuals with DM are scarce.

Aim: We aimed to investigate the association of blood HbA1c levels with adverse differences in HRV, which is an indicator of cardiac autonomic control, in adult individuals with and without DM.

Methods: Data were collected from the Midlife in the United States (MIDUS) study, and 928 individuals were analyzed for the relationship between blood HbA1c levels and HRV through a cross-sectional analysis.

Results: Participants with DM had significantly higher HRV than those without DM. The smooth curve suggested inverse relationships between blood HbA1c levels and HF- and LF-HRV seen in participants with DM but not in those without DM after controlling for all covariates (age, sex, BMI, smoking, number of drinking years and exercise). Furthermore, linear regression analysis demonstrated that elevated blood HbA1c levels did contribute to adverse differences in HF-HRV ($S\beta = -0.118$; 95% CI $-0.208, -0.027$; $P = 0.012$) and LF-HRV ($S\beta = -0.097$; 95% CI $-0.177, -0.017$; $P = 0.019$) after controlling for these covariates in participants with DM, while in participants without DM, blood HbA1c was not significantly related to adverse differences in HF-HRV ($S\beta = 0.095$; 95% CI $-0.059, 0.248$; $P = 0.228$) or LF-HRV ($S\beta = 0.043$; 95% CI $-0.103, 0.189$; $P = 0.565$). DM has a significant modifying effect on associations between blood HbA1c and adverse differences in HF-HRV (P for interaction = 0.019) and LF-HRV (P for interaction = 0.029).

Conclusions: We reported strong evidence that elevated blood levels of HbA1c were associated with adverse differences in HRV in the diabetic population but not in the nondiabetic population. This finding supported that long-term hyperglycemia is related to autonomic nerve injury in the diabetic population. Blood HbA1c might be a good indicator of cardiac autonomic neuropathy.

KEYWORDS

automatic nervous system, HbA1c, heart rate variability, cardiac autonomic neuropathy, diabetes mellitus

Introduction

The increasing prevalence of diabetes mellitus (DM) in most countries contributes to an increased risk of cardiovascular (CV) events and mortality (1, 2). Diabetic autonomic neuropathy is one of the important mechanisms in the development of CV events (3–5). As an index to evaluate autonomic nervous system (ANS) function, heart rate variability (HRV) is a well-known marker for ANS dysfunction caused by an imbalance between the sympathetic and parasympathetic nervous systems (6). Previous studies have confirmed that reduced HRV has been positively associated with high CV outcomes, including incident coronary heart disease, stroke and CV mortality (7–9). HRV may represent a target for preventing CV outcomes through medication or lifestyle changes that improve or preserve ANS function (10). Importantly, the association between HRV and CV outcomes has been shown to be stronger in the DM population (8, 9). A recent study also showed that reduced HRV may exist in the course of prediabetes (11). However, the clinical value of risk factors for identifying individuals at high risk of ANS dysfunction is unknown.

Glycosylated hemoglobin is the product of the combination of hemoglobin in red blood cells and sugars in blood through nonenzymatic reactions (12). The concentration of glycosylated hemoglobin can effectively reflect the average blood glucose level in the previous 8–12 weeks (13). Glycosylated hemoglobin consists of HbA1a, HbA1b and HbA1c. HbA1c accounts for approximately 70% of all glycosylated hemoglobin and is commonly used as a monitoring index for diabetes control (14, 15). To date, few studies have investigated the association between blood HbA1c levels and HRV. We analyzed data from the Midlife in the United States (MIDUS) study to estimate the association between blood HbA1c levels and HRV in a general adult population. The MIDUS study provided enough information on cardiac function evaluation and blood tests. Therefore, we fully investigated the relationship between blood concentrations of HbA1c and HRV in the adult population.

Methods

Study participants

This is a retrospective analysis on data from the MIDUS study conducted with 7,108 noninstitutionalized adults in 1995 (16). The MIDUS II study with 4,963 participants was the first follow-up between 2004 and 2006 (17). A total of 1255 participants in MIDUS II took part in a biomarker study (18). Each participant was invited to attend a clinical research center (the University of Wisconsin, University of California, Los Angeles or Georgetown University), and trained medical staff performed a comprehensive examination including blood biochemical markers, a comprehensive physical exam and medical history data collection (18). Of the study participants with blood biomarker data (N=1,225), some subjects had missing data (N=327). As such, our study finally included 928 adults by using a cross-section analysis. Consistent with the Declaration of Helsinki, IRB approval was obtained for data collection for the MIDUS 2 Biomarker Project at the three sites, and written consent was collected from each participant. The data used in the present study are publicly available through the Inter-University Consortium for Political and Social Research (ICPSR). All analyses were conducted in accordance with the preregistration.

Assessment of HRV

After an overnight stay at the clinical research centers, all participants were given a light breakfast without caffeine. Then, the HRV psychophysiology protocol was performed for these participants after breakfast. Electrocardiogram (ECG) electrodes were placed on the two shoulders (right and left) and the left lower quadrant. Subsequently, HRV data from this resting baseline were recorded. Analog ECG signals were digitized at 500 Hz by a 16-bit A/D conversion board (National Instruments,

Austin, TX) and passed to a microcomputer. The ECG waveform, submitted to an R-wave detection routine, was performed by custom-written software, producing an RR interval series. Errors caused by marking R-waves were revised by visual inspection. Interpolation was used for correcting ectopic beats. HF-HRV and LF-HRV were computed using an interval method for computing Fourier transforms (19). The mean value of the two measurements was calculated and further analyzed. A higher HRV represented better ANS function.

Blood biomarkers

In summary, blood samples were obtained from three examination sites (the University of Wisconsin, University of California, Los Angeles and Georgetown University). All participants underwent fasting blood sampling before breakfast, and these blood samples were analyzed in the MIDUS Biocore Lab. The glycated hemoglobin assays were performed at Meriter Labs (Madison, WI) using a Cobas Integra analyzer (Roche Diagnostics, Indianapolis, IN). See Ryff and colleagues for more details about the assessment of these blood biomarkers.

Confounding variables

The following variables were included as covariates (each measured at the biomarker clinic visit): age, sex (male, female), body mass index (BMI), smoking status, number of drinking years, and chronic conditions [history of diabetes, hypertension, heart disease and transient cerebral ischemia (TIA) or stroke]. Smoking status was dichotomized as “ever smoker” or “nonsmoker”. Exercise was defined as “whether or not the frequency of exercise was ≥ 3 /week”. Chronic conditions for the participants who had ever had CVDs were classified as “yes” or “no”. BMI was measured as weight (kg) divided by the square of height (cm).

Statistical analysis

Statistical analyses in the current study were performed by using EmpowerStats 3.0. A P value less than 0.05 was defined as a significant difference. All analyses were first conducted on participants with and without DM. The Mann-Whitney U test and chi-square test were used for comparisons between the two groups. Then, logarithmic transformation was conducted on both HF-HRV and LF-HRV values to reduce skewed distributions. Single-factor smoothing analysis was performed to assess the association between blood HbA1c levels and HRV. A multivariate linear regression model was further established to estimate the independent effect of blood HbA1c on adverse differences in HRV. Each model reported a standardized correlation coefficient ($S\beta$), and confidence intervals (CIs) had thresholds of 95%.

In the calibration analysis, blood HbA1c was assessed as an independent predictor for adverse differences in HRV. The details are as follows: 1) The crude model tested the effects of nonadjustment on adverse differences in HRV. Model 1 included age and sex. Model 2 included Model 1 and health-related confounders (BMI, smoking, number of drinking years and exercise). Similarly, a corrected smooth curve analysis was established to analyze the independent effect of blood HbA1c on adverse differences in HRV. Specifically, subgroup analyses further examined the effects of chronic conditions (history of hypertension, heart disease, and TIA or stroke) on the association of blood HbA1c with HRV. Similar to the Model 2 analysis, each subgroup analysis adjusted for age, sex, BMI, smoking, number of drinking years and exercise.

Results

Characteristics of participants

A total of 928 adult participants were analyzed for HF-HRV and LF-HRV as well as blood HbA1c. A total of 11.6% of these study participants were diagnosed with DM. Demographic data on participants with DM (N=128) and without DM (N=820) are shown in [Table 1](#). Both groups did not significantly differ in sex, smoking status, number of drinking years, HF-HRV and history of TIA or stroke. DM participants had significantly higher age and BMI; higher rates of heart disease, hypertension and cholesterol problems; and a lower frequency of exercise and HF-HRV compared with those without DM.

Elevated blood HbA1c levels contributed to adverse differences in HRV

As [Figures 1A, B](#) indicates, the single-factor smooth curve shows inverse relationships between blood HbA1c levels and HF-HRV and LF-HRV values in participants with DM but not in those without DM. After controlling for all covariates, including age, sex, BMI, smoking, number of drinking years and exercise, the corrected smooth curve suggested similar results that significant relationships between blood HbA1c levels were seen in participants with DM but not in those without DM ([Figures 2A, B](#)).


Furthermore, linear regression analysis demonstrated that elevated blood HbA1c levels did contribute to adverse differences in HF-HRV ($S\beta=-0.118$; 95% CI -0.208, -0.027; $P=0.012$) and LF-HRV ($S\beta=-0.097$; 95% CI -0.177, -0.017; $P=0.019$) in Model 2 after controlling for all covariates in participants with DM, as shown in [Table 2](#). In participants without DM, blood HbA1c was not significantly related to adverse differences in HF-HRV ($S\beta=0.095$; 95% CI -0.059,

TABLE 1 Characteristics of participants (N=928).

Variables	With DM (N=108)	Without DM (N=820)	P value
Age (years)	55 (48-62)	53 (44-61)	0.015
Gender (male), n (%)	49 (45.37)	373 (45.49)	0.982
BMI (kg/m ²)	31.74 (28.39-35.62)	28.03 (25.01-32.32)	<0.001
Ever smoker, n (%)	59 (54.63)	415 (50.61)	0.432
Number of drinking years	5 (2-18.25)	5 (2-14.62)	0.127
Frequency of exercises ≥ 3 / week, n (%)	74 (68.52)	636 (77.56)	0.037
Natural log of LF-HRV (0.04-0.15 Hz)	5.32 (4.54-5.93)	5.81 (4.91-6.56)	<0.001
Natural log of HF-HRV (0.15-0.50 Hz)	4.88 (4.00-5.65)	4.99 (4.05-5.75)	0.237
CVD history			
Heart disease, n (%)	18 (16.67)	66 (8.05)	0.003
Hypertension, n (%)	64 (59.26)	254 (30.98)	<0.001
TIA or stroke, n (%)	6 (5.56)	24 (2.93)	0.147
Cholesterol problems, n (%)	68 (62.96)	326 (39.76)	<0.001
Blood analysis			
HemoglobinA1c (%)	7.13 (6.37-8.78)	5.74 (5.50-6.04)	<0.001
Fasting Glucose (mg/dL)	117.00 (104.00-153.00)	95 (89.00-102.00)	<0.001
Fasting Insulin (uIU/mL)	15.50 (10.00-24.25)	9.00 (6.00-16.00)	<0.001

M (IQR) for non-normally distributed variables, and n (%) for categoric variables.

DM, diabetes mellitus; BMI, body mass index; LF-HRV, Low frequency-heart rate variability; HF-HRV, High frequency heart rate variability; CVD, cardiovascular disease; TIA, transient ischemic attack.



0.248; $P = 0.228$) or LF-HRV ($S\beta = 0.043$; 95% CI -0.103, 0.189; $P = 0.565$).

Subgroup analyses for the association of blood HbA1c with HRV

Subgroup analyses were further evaluated for the effects of chronic conditions (diabetes, hypertension, heart disease and TIA or stroke) on the association of blood HbA1c with HRV. As shown in Table 3, we found that DM had a significant modifying effect on associations between blood HbA1c and adverse

differences in HF-HRV (P for interaction = 0.019) and LF-HRV (P for interaction = 0.029). The results further clarified the differences in the association between blood HbA1c and HRV among diabetic participants. However, we did not observe that hypertension, heart disease and TIA or stroke had no modifying effect on the association.

Discussion

In this cross-sectional study in an adult population, our findings were that diabetic patients demonstrated a significant




FIGURE 2

Corrected smooth curve for the association between blood HbA1c and HRV [As (A, B) indicates, the corrected smooth curve suggested inverse relationships between blood HbA1c levels and HF-HRV and LF-HRV values in participants with DM ($P < 0.05$) but not in those without DM ($P > 0.05$) after controlling for all covariates, including age, sex, BMI, smoking, number of drinking years and exercise].

TABLE 2 Multiple linear regression analysis for relationship between blood hemoglobinA1c and HRV.

Variables	LF-HRV			HF-HRV		
	S β	95% CI	P Value	S β	95% CI	P Value
With DM						
Crude Model	-0.075	(-0.162, 0.013)	0.099	-0.114	(-0.206, -0.021)	0.017
Model 1	-0.094	(-0.174, -0.014)	0.023	-0.120	(-0.213, -0.028)	0.012
Model 2	-0.097	(-0.177, -0.017)	0.019	-0.118	(-0.208, -0.027)	0.012
Without DM						
Crude Model	-0.238	(-0.387, -0.090)	0.002	-0.046	(-0.196, 0.103)	0.543
Model 1	-0.024	(-0.167, 0.118)	0.737	0.103	(-0.046, 0.252)	0.176
Model 2	0.043	(-0.103, 0.189)	0.565	0.095	(-0.059, 0.248)	0.228

Crude Model : No adjustment.

Model 1: Adjusted for age and gender.

Model 2: Adjusted for age, gender, BMI, ever smoker, number of drinking years and exercise.

DM, diabetes mellitus; LF-HRV, low frequency-heart rate variability; HF-HRV, High frequency heart rate variability; BMI, body mass index.

decrease in LF-HRV and HF-HRV. We observed that elevated blood levels of HbA1c are strongly and negatively related to adverse differences in HF-HRV and LF-HRV in individuals with DM but not in individuals without DM, which may be explained by the deleterious metabolic effects of hyperglycemia on cardiac autonomic nerves. The associations remained significant after adjustment for demographic characteristics and lifestyle (age, sex, BMI, smoking, number of drinking years and exercise) in the diabetic population. Controlling blood glucose levels so that they are stable and at normal levels might improve ANS dysfunction in the diabetic population, which is beneficial to prevent adverse CV events.

ANS dysfunction is characterized by decreased parasympathetic activity and increased sympathetic activity, indicating a need for vigilance of chronic diseases (20). Importantly, common chronic diseases, including cancer, rheumatoid arthritis, myocardial infarctions, obesity and metabolic syndrome, hypertension and

depression, are related to elevated sympathetic activity and reduced parasympathetic activity (21–26). Previous studies have also shown that diabetes has an adverse effect on HRV (5, 27). One study reported that elderly individuals with DM may have worse parasympathetic control (27). Another meta-analysis involving 25 case-control studies with 2,932 type 2 diabetes patients suggested that blood glucose and HbA1c were associated with several HRV parameters (5). Consistently, our results again demonstrated that high blood HbA1c levels contributed to an increased risk of adverse differences in HRV in subjects with DM. In contrast, we observed that the association was not significant in individuals without DM. A reasonable explanation may be that DM is a metabolic disease responsible for cardiac autonomic neuropathy that affects both sympathetic and parasympathetic fibers, reflecting the fact that DM leads to ANS dysfunction.

Interestingly, our results showed that blood glucose levels were not associated with LF-HRV and HF-HRV in DM or non-

TABLE 3 Subgroup analyses for association between blood hemoglobinA1c and HRV by adding "CVD history" as stratification variables.

Variables	n	LF-HRV				HF-HRV			
		Sβ	95% CI	P Value	P #	Sβ	95% CI	P Value	P #
Ever had DM (YES)	108	-0.097	(-0.177, -0.017)	0.019	0.029	-0.118	(-0.208, -0.027)	0.012	0.019
Ever had DM (NO)	820	0.043	(-0.103, 0.189)	0.565		0.095	(-0.059, 0.248)	0.228	
Ever had heart disease (YES)	84	-0.102	-0.337, 0.134	0.392	0.901	-0.058	-0.305, 0.189	0.643	0.916
Ever had heart disease (NO)	884	-0.091	-0.154, -0.029	0.004		-0.072	-0.138, -0.006	0.032	
Ever had hypertension (YES)	318	-0.133	-0.239, -0.027	0.014	0.419	-0.102	-0.210, 0.007	0.066	0.854
Ever had hypertension (NO)	610	-0.047	-0.122, 0.027	0.210		-0.043	-0.122, 0.035	0.278	
Ever had TIA or stroke (YES)	30	-0.468	-0.882, -0.053	0.029	0.063	-0.343	-0.743, 0.058	0.090	0.172
Ever had TIA or stroke (NO)	898	-0.070	-0.132, -0.009	0.025		-0.044	-0.109, 0.021	0.185	
Ever had cholesterol problems (YES)	394	-0.166	-0.210, -0.023	0.015	0.904	-0.095	-0.194, 0.004	0.059	0.464
Ever had cholesterol problems (NO)	534	-0.059	-0.140, 0.022	0.156		-0.023	-0.109, 0.062	0.593	

Adjusted for age, gender, BMI, ever smoker, number of drinking years and exercise.

P#: P interaction.

DM, diabetes mellitus; CVD, cardiovascular disease; LF-HRV, low frequency-heart rate variability; HF-HRV, High frequency heart rate variability; TIA, transient ischemic attack; BMI, body mass index.

DM participants, which seems contradictory to the above results (Supplementary Materials Table 1). A possible explanation for this uncorrelated association is that blood glucose levels are not truly a stable biomarker to evaluate the degree of diabetes control compared with blood HbA1c. A single blood glucose test only reflects the immediate blood glucose situation, which is affected by many factors, such as recent diet, exercise and medicines. HbA1c reflects the level of blood glucose in the previous 2-3 months, and the interference factors are relatively small, which can better reflect the overall control of diabetes (13–15). In fact, our study participants were from different American communities. Although their physical condition was good, participants with DM or chronic diseases were treated with medicines, which may be a powerful explanation for our contradictory results. The association of blood HbA1c with LF- and HF-HRV is logical in DM participants.

More interestingly, we further observed that blood insulin levels were related to reduced LF-HRV and HF-HRV in DM and non-DM participants, respectively (Supplementary Materials Table 2). Blood insulin, the main hormone that reduces blood glucose in the body, is an important indicator for the diagnosis and typing of diabetes. Its level in the blood is closely related to the degree of blood glucose control. A clinical study showed that parasympathetic activity can be triggered by elevated blood levels of glucose *via* increased insulin secretion in a healthy population (28). This may partly explain our results of why blood insulin levels are closely related to HRV in non-DM participants.

To the best of our knowledge, few data have been reported on the association between dyslipidemia and HRV in the literature. Several studies have shown that lowering blood low-density

lipoprotein (LDL) levels by statin therapy contributes to beneficial effects in HRV parameters (29, 30). In our study, although a history of cholesterol problems had no interaction effect on blood HbA1c with LF- and HF-HRV, elevated blood HbA1c levels were significantly related to adverse differences in HRV in participants with a history of cholesterol problems rather than those who had never had cholesterol problems, which was consistent with two previous results (29, 30). Previous studies reported that increased blood pressure was associated with decreased HRV (5, 31) and that impaired ANS function precedes the progression of clinical hypertension (32). Coincidentally, high blood HbA1c levels were more significantly linked with adverse differences in HRV in participants with a history of hypertension than in participants without a history of hypertension. However, we did not observe a significant association between blood HbA1c and HRV in participants with a history of heart disease, which has rarely been reported in the literature. Autonomic nervous system dysfunction caused by organic lesions of the heart may explain this phenomenon. Moreover, we found that a history of TIA or stroke had no impact on the relationship, which may be related to the fact that autonomic nervous system function is not closely related to cerebrovascular diseases.

There are several strengths in our study. This study had a large sample size from the general population and a community-based design, which provided high-quality blood HbA1c and HRV data. Blood HbA1c can reflect diabetes control over the previous few months. Repeating HRV measurements allowed us to adjust HRV error. Several previous studies have shown that BMI, exercise and other living habits were associated with HRV (33, 34). We adjusted for demographic characteristics (age and

sex) and lifestyle (BMI, smoking, drinking and exercise), providing a more reliable association between blood HbA1c and HRV. Moreover, subgroup analysis by using “CVDs” as covariates determined whether CVDs had an obvious modifying effect on the independent relationship.

There were several notable limitations in the present study. First, due to the inherent disadvantages of cross-sectional analysis in establishing causality, it was difficult to confirm whether elevated blood HbA1c precedes adverse differences in HRV or impaired ANS function. Second, all participants who took part in this study needed to be relatively healthy to go to the three clinical research centers of the MIDUS study. Some individuals with a history of serious diseases were not included; thus, this may have led to potential selection bias. Third, all recruited participants with a history of DM were included in this study, but the specific type of diabetes, duration of the disease and medications were unclear. We could not rule out the interference of these confounding factors on the relationship between blood HbA1c and HRV. Fourth, the variables (history of CVDs) used for subgroup analysis mainly came from participants’ self-reports by a questionnaire survey; thus, undiagnosed disease history in many participants might cause some error in the results. Fifth, of all participants with blood biomarker data (N=1,225), only 928 study samples were analyzed in our study, and 327 individuals who had missing data were not further analyzed. Sixth, there is established evidence that LF-HRV is poor indicator of sympathetic nervous system (SNS) activity (35, 36), which are inconsistent with our results. More studies are needed to resolve this controversy in the future. Finally, the lack of an association between HRV and HbA1C in the non-DM group could easily be due to the constricted range of HbA1c in this group. By definition, non-DM people will tend to have much lower HbA1C values, which is evident in the shorter line in Figures 1 and 2. Therefore, diabetes-related differences on the association between HRV and HbA1C need to be further clarified.

We first reported that elevated blood HbA1c levels contributed to adverse differences of HRV in the diabetic population but not in the nondiabetic population. The detrimental effects of impaired glucose metabolism on HRV suggested that blood HbA1c might be a potential biomarker for predicting cardiac autonomic neuropathy.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

References

1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Sirtan C, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of

Ethics statement

The studies involving human participants were reviewed and approved by Consistent with the Declaration of Helsinki, IRB approval was obtained for data collection for the MIDUS 2 Biomarker Project at the three sites, and written consent was collected from each participant. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

YH and HC completed data analysis and first draft writing. DH and RW completed data supervision and modification. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from the National Natural Science Foundation of China (NSFC 82060059) and the General Project of the Jiangxi Natural Science Foundation (20212BAB206055).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fendo.2022.921287/full#supplementary-material>

vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* (2010) 375(9733):2215–22. doi: 10.1016/S0140-6736(10)60484-9

2. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* (2020) 41(2):255–323. doi: 10.1093/eurheartj/ehz486
3. Ferrannini G, Manca ML, Magnoni M, Andreotti F, Andreini D, Latini R, et al. Coronary artery disease and type 2 diabetes: A proteomic study. *Diabetes Care* (2020) 43(4):843–51. doi: 10.2337/dc19-1902
4. Andersen ST, Witte DR, Fleischer J, Andersen H, Lauritzen T, Jørgensen ME, et al. Risk factors for the presence and progression of cardiovascular autonomic neuropathy in type 2 diabetes: ADDITION-Denmark. *Diabetes Care* (2018) 41(12):2586–94. doi: 10.2337/dc18-1411
5. Benichou T, Pereira B, Mermillod M, Tauveron I, Pfabigan D, Maqdasy S, et al. Heart rate variability in type 2 diabetes mellitus: A systematic review and meta-analysis. *PLoS One* (2018) 13(4):e0195166. doi: 10.1371/journal.pone
6. Heart rate variability. standards of measurement, physiological interpretation, and clinical use. task force of the European society of cardiology and the North American society of pacing and electrophysiology. *Eur Heart J* (1996) 17(3):354–81.
7. Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. *Circulation* (1993) 88(3):927–34. doi: 10.1161/01.CIR.88.3.927
8. Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA, et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC study. *Atherosclerotic Risk In Communities Circ* (2000) 102(11):1239–44. doi: 10.1161/01.CIR.102.11.1239
9. Liao D, Carnethon M, Evans GW, Cascio WE, Heiss G. Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: The atherosclerosis risk in communities (ARIC) study. *Diabetes* (2002) 51(12):3524–31. doi: 10.2337/diabetes.51.12.3524
10. Stinear CM, Lang CE, Zeiler S, Byblow WD. Advances and challenges in stroke rehabilitation. *Lancet Neurol* (2020) 19(4):348–60. doi: 10.1016/S1474-4422(19)30415-6
11. Coopmans C, Zhou TL, Henry RMA, Heijman J, Schaper NC, Koster A, et al. Both prediabetes and type 2 diabetes are associated with lower heart rate variability: The maastrecht study. *Diabetes Care* (2020) 43(5):1126–33. doi: 10.2337/dc19-2367
12. Goldstein DE. Is glycosylated hemoglobin clinically useful? *N Engl J Med* (1984) 310(6):384–5. doi: 10.1056/NEJM198402093100609
13. Noh J. Impact of social distancing due to coronavirus disease 2019 on the changes in glycosylated hemoglobin level in people with type 2 diabetes mellitus (*Diabetes metab J* 2021;45:109-14). *Diabetes Metab J* (2021) 45(2):275–6. doi: 10.4093/dmj.2020.0288
14. Yazdanpanah S, Rabiee M, Tahriri M, Abdolrahim M, Rajab A, Jazayeri HE, et al. Evaluation of glycated albumin (GA) and GA/HbA1c ratio for diagnosis of diabetes and glycemic control: A comprehensive review. *Crit Rev Clin Lab Sci* (2017) 54(4):219–32. doi: 10.1080/10408363.2017.1299684
15. Weykamp C. HbA1c: A review of analytical and clinical aspects. *Ann Lab Med* (2013) 33(6):393–400. doi: 10.3343/alm.2013.33.6.393
16. Brim OG, Baltes PB, Bumpass LL, Cleary PD, Featherman DL, Hazzard WR, et al. Midlife in the United States (MIDUS 1), 1995–1996 (ICPSR 2760; version V18). (2019). doi: 10.3886/ICPSR02760.v18
17. Ryff CD, Seeman T, Weinstein MICPSR. Midlife in the united states (MIDUS 2): Biomarker project, 2004–2009 (ICPSR 29282; version V9). (2019). doi: 10.3886/ICPSR29282.v9
18. Ryff C, Almeida DM, Ayanian J, Carr DS, Cleary PD, Coe C, et al. Midlife in the united states (MIDUS 2), 2004–2006 (ICPSR 4652; version V7). (2017). doi: 10.3886/ICPSR04652.v7
19. DeBoer RW, Karemaker JM, Strackee J. Comparing spectra of a series of point events particularly for heart rate variability data. *IEEE Trans BioMed Eng* (1984) 31(4):384–7. doi: 10.1109/TBME.1984.325351
20. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. *J Am Coll Cardiol* (1993) 22(4 Suppl A):72A–84A. doi: 10.1016/0735-1097(93)90466-e
21. Fagundes CP, Murray DM, Hwang BS, Gouin JP, Thayer JF, Sollers JJ3rd, et al. Sympathetic and parasympathetic activity in cancer-related fatigue: More evidence for a physiological substrate in cancer survivors. *Psychoneuroendocrinology* (2011) 36(8):1137–47. doi: 10.1016/j.psyneuen.202121.0A2dla0n0A5
22. Adlan AM, Paton JF, Lip GY, Kitas GD, Fisher JP. Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis. *J Physiol* (2017) 595(3):967–81. doi: 10.1113/JP272944
23. Malliani A, Montano N. Sympathetic overactivity in ischaemic heart disease. *Clin Sci (Lond)* (2004) 106(6):567–8. doi: 10.1042/CS20040068
24. Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. *J Diabetes Res* (2015) 2015:341583.
25. Haspula D, Clark MA. Neuroinflammation and sympathetic overactivity: Mechanisms and implications in hypertension. *Auton Neurosci* (2018) 210:10–7. doi: 10.1016/j.autneu.2018.01.002
26. Chen X, Yang R, Kuang D, Zhang L, Lv R, Huang X, et al. Heart rate variability in patients with major depression disorder during a clinical autonomic test. *Psychiatry Res* (2017) 256:207–11. doi: 10.1016/j.psychres.2017.06.041
27. Ribeiro JJS, Pereira R, Valença Neto PF, Freire IV, Casotti CA, Reis MGD. Relationship between diabetes mellitus and heart rate variability in community-dwelling elders. *Medicina (Kaunas)* (2017) 53(6):375–9. doi: 10.1016/j.medic.2017.12.001
28. Stockhorst U, Huenig A, Ziegler D, Scherbaum WA. Unconditioned and conditioned effects of intravenous insulin and glucose on heart rate variability in healthy men. *Physiol Behav* (2011) 103(1):31–8. doi: 10.1016/j.physbeh.2011.01.014
29. Badae AR, Nedelcu L, Valeanu M, Zdrenghea D. The relationship between serum lipid fractions and heart rate variability in diabetic patients with statin therapy. *Clujul Med* (2014) 87(3):152–8. doi: 10.15386/cjmed-313
30. Pehlivanidis AN, Athyros VG, Demetriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. *Atherosclerosis*. (2001) 157(2):463–9. doi: 10.1016/S0021-9150(00)00746-2
31. de Andrade PE, do Amaral JAT, Paiva LDS, Adami F, Raimudo JZ, Valenti VE, et al. Reduction of heart rate variability in hypertensive elderly. *Blood Press* (2017) 26(6):350–8. doi: 10.1080/08037051.2017.1354285
32. Schroeder EB, Liao D, Chambless LE, Prineas RJ, Evans GW, Heiss G. Hypertension, blood pressure, and heart rate variability: the atherosclerosis risk in communities (ARIC) study. *Hypertension* (2003) 42(6):1106–11. doi: 10.1161/01.HYP.0000100444.71069.73
33. Villafaina S, Collado-Mateo D, Fuentes JP, Merellano-Navarro E, Gusi N. Physical exercise improves heart rate variability in patients with type 2 diabetes: A systematic review. *Curr Diabetes Rep* (2017) 17(11):110. doi: 10.1007/s11892-017-0941-9
34. Yadav RL, Yadav PK, Yadav LK, Agrawal K, Sah SK, Islam MN. Association between obesity and heart rate variability indices: An intuition toward cardiac autonomic alteration - a risk of CVD. *Diabetes Metab Syndr Obes* (2017) 10:57–64. doi: 10.2147/DMSO.S123935
35. Reyes del Paso GA, Langewitz W, Mulder LJ, van Roon A, Dusчек S. The utility of low frequency heart rate variability as an index of sympathetic cardiac tone: A review with emphasis on a reanalysis of previous studies. *Psychophysiology* (2013) 50(5):477–87. doi: 10.1111/psyp.12027
36. Billman GE. The LF/HF ratio does not accurately measure cardiac sympatho-vagal balance. *Front Physiol* (2013) 4:26. doi: 10.3389/fphys.2013.00026